Navigation Links
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Date:6/23/2008

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
4. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. TorreyPines Therapeutics Reports Third Quarter 2007 Results
6. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
8. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
9. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
10. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
11. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 Applied ... mechanistic modeling to drug research and development, today ... Co-Founder, President, and CEO of Applied BioMath, will ... Informatics and Modeling (BAGIM) Meeting on Thursday January ... Cambridge , MA.   Dr. Burke,s talk ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December 2016, ... (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award of a ... Defense has announced the award of a new Advanced Regenerative Manufacturing Institute (ARMI). ...
(Date:1/18/2017)... San Francisco, CA (PRWEB) , ... January 18, ... ... delighted to report the publishing of the latest paper by its Science Editor, ... Medical Microbiology (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October ...
(Date:1/18/2017)... , Jan. 18, 2017 /PRNewswire/ - SQI ... sciences and diagnostics company that develops and commercializes ... ("SQI" or the "Company"), today announced that ... Inc. ("Kingsdale"), has resigned from its Board of ... changes to securities regulations that have limited both ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
Breaking Biology News(10 mins):